Xuesen Dong

ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 34

Top Venues

Oncogene

Nature communications

Proceedings of the National Academy of Sciences of the United States of America

Pharmaceuticals (Basel, Switzerland)

University of British Columbia

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University of British Columbia

Canada

Associate Professor :: Urologic Sciences

Publications

Majid Pornour, Hee-Young Jeon, Hyunju Ryu, Sudeep Khadka, Rui Xu, Hegang Chen, Arif Hussain, Hung-Ming Lam, Zhihao Zhuang, Htoo Zarni Oo, Martin Gleave, Xuesen Dong, Qianben Wang, Christopher Barbieri, Jianfei Qi
USP11 promotes prostate cancer progression by up-regulating AR and c-Myc activity. Proceedings of the National Academy of Sciences of the United States of America 121 (31) (2024)
Majid Pornour, Hee-Young Jeon, Hyunju Ryu, Sudeep Khadka, Rui Xu, Hegang Chen, Arif Hussain, Hung-Ming Lam, Zhihao Zhuang, Htoo Zarni Oo, Martin Gleave, Xuesen Dong, Qianben Wang, Christopher Barbieri, Jianfei Qi
USP11 promotes prostate cancer progression by up-regulating AR and c-Myc activity. Proceedings of the National Academy of Sciences of the United States of America 121 (31) (2024)
Majid Pornour, Hee-Young Jeon, Hyunju Ryu, Sudeep Khadka, Rui Xu, Hegang Chen, Arif Hussain, Hung-Ming Lam, Zhihao Zhuang, Htoo Zarni Oo, Martin Gleave, Xuesen Dong, Qianben Wang, Christopher Barbieri, Jianfei Qi
USP11 promotes prostate cancer progression by up-regulating AR and c-Myc activity. Proceedings of the National Academy of Sciences of the United States of America 121 (31) (2024)
Takuya Tsujino, Tomoaki Takai, Kunihiko Hinohara, Fu Gui, Takeshi Tsutsumi, Xiao Bai, Chenkui Miao, Chao Feng, Bin Gui, Zsofia Sztupinszki, Antoine Simoneau, Ning Xie, Ladan Fazli, Xuesen Dong, Haruhito Azuma, Atish D Choudhury, Kent W Mouw, Zoltan Szallasi, Lee Zou, Adam S Kibel, Li Jia
CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer. Nature communications 14 (1) (2023)
Zhuoyuan Lin, Shivani Agarwal, Song Tan, Hongshun Shi, Xiaodong Lu, Zhipeng Tao, Xuesen Dong, Xu Wu, Jonathan C Zhao, Jindan Yu
Palmitoyl acyltransferase ZDHHC7 inhibits androgen receptor and suppresses prostate cancer. Oncogene (2023)
Victor M Matias-Barrios, Xuesen Dong
The Implication of Topoisomerase II Inhibitors in Synthetic Lethality for Cancer Therapy. Pharmaceuticals (Basel, Switzerland) 16 (1) (2023)
Victor M Matias-Barrios, Xuesen Dong
The Implication of Topoisomerase II Inhibitors in Synthetic Lethality for Cancer Therapy. Pharmaceuticals (Basel, Switzerland) 16 (1) (2023)
Victor M Matias-Barrios, Xuesen Dong
The Implication of Topoisomerase II Inhibitors in Synthetic Lethality for Cancer Therapy. Pharmaceuticals (Basel, Switzerland) 16 (1) (2023)
Takuya Tsujino, Tomoaki Takai, Kunihiko Hinohara, Fu Gui, Takeshi Tsutsumi, Xiao Bai, Chenkui Miao, Chao Feng, Bin Gui, Zsofia Sztupinszki, Antoine Simoneau, Ning Xie, Ladan Fazli, Xuesen Dong, Haruhito Azuma, Atish D Choudhury, Kent W Mouw, Zoltan Szallasi, Lee Zou, Adam S Kibel, Li Jia
CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer. Nature communications 14 (1) (2023)
Victor M Matias-Barrios, Xuesen Dong
The Implication of Topoisomerase II Inhibitors in Synthetic Lethality for Cancer Therapy. Pharmaceuticals (Basel, Switzerland) 16 (1) (2023)
Takuya Tsujino, Tomoaki Takai, Kunihiko Hinohara, Fu Gui, Takeshi Tsutsumi, Xiao Bai, Chenkui Miao, Chao Feng, Bin Gui, Zsofia Sztupinszki, Antoine Simoneau, Ning Xie, Ladan Fazli, Xuesen Dong, Haruhito Azuma, Atish D Choudhury, Kent W Mouw, Zoltan Szallasi, Lee Zou, Adam S Kibel, Li Jia
CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer. Nature communications 14 (1) (2023)
Takuya Tsujino, Tomoaki Takai, Kunihiko Hinohara, Fu Gui, Takeshi Tsutsumi, Xiao Bai, Chenkui Miao, Chao Feng, Bin Gui, Zsofia Sztupinszki, Antoine Simoneau, Ning Xie, Ladan Fazli, Xuesen Dong, Haruhito Azuma, Atish D Choudhury, Kent W Mouw, Zoltan Szallasi, Lee Zou, Adam S Kibel, Li Jia
CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer. Nature communications 14 (1) (2023)
Takuya Tsujino, Tomoaki Takai, Kunihiko Hinohara, Fu Gui, Takeshi Tsutsumi, Xiao Bai, Chenkui Miao, Chao Feng, Bin Gui, Zsofia Sztupinszki, Antoine Simoneau, Ning Xie, Ladan Fazli, Xuesen Dong, Haruhito Azuma, Atish D Choudhury, Kent W Mouw, Zoltan Szallasi, Lee Zou, Adam S Kibel, Li Jia
CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer. Nature communications 14 (1) (2023)
Takuya Tsujino, Tomoaki Takai, Kunihiko Hinohara, Fu Gui, Takeshi Tsutsumi, Xiao Bai, Chenkui Miao, Chao Feng, Bin Gui, Zsofia Sztupinszki, Antoine Simoneau, Ning Xie, Ladan Fazli, Xuesen Dong, Haruhito Azuma, Atish D Choudhury, Kent W Mouw, Zoltan Szallasi, Lee Zou, Adam S Kibel, Li Jia
CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer. Nature communications 14 (1) (2023)
Martin K Bakht, John J Hayward, Farsheed Shahbazi-Raz, Magdalena Skubal, Ryo Tamura, Keith F Stringer, Daniel Meister, Varadha Balaji Venkadakrishnan, Hui Xue, Adam Pillon, Mathew Stover, Adam Tronchin, Bre-Anne Fifield, Lavleen K Mader, Sheng-Yu Ku, Gi Jeong Cheon, Keon-Wook Kang, Yuzhuo Z Wang, Xuesen Dong, Himisha Beltran, Jan Grimm, Lisa A Porter, John F Trant
Identification of alternative protein targets of glutamate-ureido-lysine associated with PSMA tracer uptake in prostate cancer cells. Proceedings of the National Academy of Sciences of the United States of America 119 (4) (2022)
Liancheng Fan, Yiming Gong, Yuman He, Wei-Qiang Gao, Xuesen Dong, Baijun Dong, Helen He Zhu, Wei Xue
TRIM59 is suppressed by androgen receptor and acts to promote lineage plasticity and treatment-induced neuroendocrine differentiation in prostate cancer. Oncogene 42 (8) (2022)
Liancheng Fan, Yiming Gong, Yuman He, Wei-Qiang Gao, Xuesen Dong, Baijun Dong, Helen He Zhu, Wei Xue
TRIM59 is suppressed by androgen receptor and acts to promote lineage plasticity and treatment-induced neuroendocrine differentiation in prostate cancer. Oncogene 42 (8) (2022)
Feifei Sun, Xinpei Wang, Jing Hu, Junmei Liu, Xin Wang, Wenqiao Jia, Zeyuan Yu, Lin Gao, Baokai Dou, Ru Zhao, Tingting Feng, Xueli Wang, Wenbo Zhang, Hui Liu, Kaihua Liu, Yang Shao, Xuesen Dong, Bo Han
RUVBL1 promotes enzalutamide resistance of prostate tumors through the PLXNA1-CRAF-MAPK pathway. Oncogene 41 (23) (2022)
Liancheng Fan, Yiming Gong, Yuman He, Wei-Qiang Gao, Xuesen Dong, Baijun Dong, Helen He Zhu, Wei Xue
TRIM59 is suppressed by androgen receptor and acts to promote lineage plasticity and treatment-induced neuroendocrine differentiation in prostate cancer. Oncogene (2022)
Zhuohui Lin, Mariia Radaeva, Artem Cherkasov, Xuesen Dong
Lin28 Regulates Cancer Cell Stemness for Tumour Progression. Cancers 14 (19) (2022)
Liancheng Fan, Yiming Gong, Yuman He, Wei-Qiang Gao, Xuesen Dong, Baijun Dong, Helen He Zhu, Wei Xue
TRIM59 is suppressed by androgen receptor and acts to promote lineage plasticity and treatment-induced neuroendocrine differentiation in prostate cancer. Oncogene 42 (8) (2022)
Mariia Radaeva, Chia-Hao Ho, Ning Xie, Sijie Zhang, Joseph Lee, Liangliang Liu, Nada Lallous, Artem Cherkasov, Xuesen Dong
Discovery of Novel Lin28 Inhibitors to Suppress Cancer Cell Stemness. Cancers 14 (22) (2022)
Yang Yi, Yanqiang Li, Chao Li, Longxiang Wu, Dongyu Zhao, Fuxi Li, Ladan Fazli, Rui Wang, Long Wang, Xuesen Dong, Wei Zhao, Kaifu Chen, Qi Cao
Methylation-dependent and -independent roles of EZH2 synergize in CDCA8 activation in prostate cancer. Oncogene 41 (11) (2022)
Liancheng Fan, Yiming Gong, Yuman He, Wei-Qiang Gao, Xuesen Dong, Baijun Dong, Helen He Zhu, Wei Xue
TRIM59 is suppressed by androgen receptor and acts to promote lineage plasticity and treatment-induced neuroendocrine differentiation in prostate cancer. Oncogene 42 (8) (2022)
Lingfan Xu, Yu Yin, Yanjing Li, Xu-Feng Chen, Yan Chang, Hong Zhang, Juan Liu, James Beasley, Patricia McCaw, Haoyue Zhang, Sarah P Young, Jeff Groth, Qianben Wang, Jason W Locasale, Xia Gao, Dean G Tang, Xuesen Dong, Yiping He, Daniel George, Hailiang Hu, Jiaoti Huang
A glutaminase isoform switch drives therapeutic resistance and disease progression of prostate cancer. Proceedings of the National Academy of Sciences of the United States of America 118 (13) (2021)
Yang Yi, Yanqiang Li, Qingshu Meng, Qiaqia Li, Fuxi Li, Bing Lu, Jiangchuan Shen, Ladan Fazli, Dongyu Zhao, Chao Li, Weihua Jiang, Rui Wang, Qipeng Liu, Aileen Szczepanski, Qianru Li, Wei Qin, Adam B Weiner, Tamara L Lotan, Zhe Ji, Sundeep Kalantry, Lu Wang, Edward M Schaeffer, Hengyao Niu, Xuesen Dong, Wei Zhao, Kaifu Chen, Qi Cao
A PRC2-independent function for EZH2 in regulating rRNA 2'-O methylation and IRES-dependent translation. Nature cell biology 23 (4) (2021)
Songhui Xu, Lingling Fan, Hee-Young Jeon, Fengbo Zhang, Xiaolu Cui, McKayla B Mickle, Guihong Peng, Arif Hussain, Ladan Fazli, Martin E Gleave, Xuesen Dong, Jianfei Qi
p300-Mediated Acetylation of Histone Demethylase JMJD1A Prevents Its Degradation by Ubiquitin Ligase STUB1 and Enhances Its Activity in Prostate Cancer. Cancer research 80 (15) (2020)
Lin Gao, Wenbo Zhang, Jing Zhang, Junmei Liu, Feifei Sun, Hui Liu, Jing Hu, Xin Wang, Xueli Wang, Peng Su, Shouzhen Chen, Sifeng Qu, Benkang Shi, Xueting Xiong, Weiwen Chen, Xuesen Dong, Bo Han
KIF15-Mediated Stabilization of AR and AR-V7 Contributes to Enzalutamide Resistance in Prostate Cancer. Cancer research 81 (4) (2020)
Xinjun Li, Meng Jiao, Jing Hu, Mei Qi, Jing Zhang, Mingfeng Zhao, Hui Liu, Xueting Xiong, Xuesen Dong, Bo Han
miR-30a inhibits androgen-independent growth of prostate cancer via targeting MYBL2, FOXD1, and SOX4. The Prostate 80 (9) (2020)
Xuesen Dong, Ruiqi Chen
Understanding aberrant RNA splicing to facilitate cancer diagnosis and therapy. Oncogene 39 (11) (2019)
Tingting Feng, Ru Zhao, Feifei Sun, Qiqi Lu, Xueli Wang, Jing Hu, Shiguan Wang, Lin Gao, Qianqian Zhou, Xueting Xiong, Xuesen Dong, Lin Wang, Bo Han
TXNDC9 regulates oxidative stress-induced androgen receptor signaling to promote prostate cancer progression. Oncogene 39 (2) (2019)
Subing Cao, Tianfang Ma, Nathan Ungerleider, Claire Roberts, Margaret Kobelski, Lianjin Jin, Monica Concha, Xia Wang, Melody Baddoo, Holly M Nguyen, Eva Corey, Ladan Fazli, Elisa Ledet, Rubin Zhang, Jonathan L Silberstein, Wensheng Zhang, Kun Zhang, Oliver Sartor, Xuesen Dong, Erik K Flemington, Yan Dong
Circular RNAs add diversity to androgen receptor isoform repertoire in castration-resistant prostate cancer. Oncogene 38 (45) (2019)
Sen Zhu, Dongyu Zhao, Chao Li, Qiaqia Li, Weihua Jiang, Qipeng Liu, Rui Wang, Ladan Fazli, Yinan Li, Lili Zhang, Yang Yi, Qingshu Meng, Wanyi Wang, Guangyu Wang, Min Zhang, Xiongbing Zu, Wei Zhao, Tuo Deng, Jindan Yu, Xuesen Dong, Kaifu Chen, Qi Cao
BMI1 is directly regulated by androgen receptor to promote castration-resistance in prostate cancer. Oncogene 39 (1) (2019)
Yinan Li, Qingfu Zhang, Jessica Lovnicki, Ruiqi Chen, Ladan Fazli, Yuzhuo Wang, Martin Gleave, Jiaoti Huang, Xuesen Dong
SRRM4 gene expression correlates with neuroendocrine prostate cancer. The Prostate 79 (1) (2018)

Xuesen Dong.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Xuesen Dong